Molecular
Molecular

Alinity m HCV Assay

hcv_amp_kit_us_dsc_0295_1.png


Accurate quantitation is critical to aid in diagnosis and faster initiation of Hepatitis C treatment. The Alinity m HCV assay is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay to detect and quantitate hepatitis C virus (HCV) RNA in human serum or plasma.

  • Dual probe assay within a highly conserved target region of the virus
  • Comprehensive coverage of all genotypes to very low viral load (8.50 IU/mL for plasma and 7.96 IU/mL for serum) to support detection of SVR
  • Confirmation of active HCV infection and viral load in the same test provides operational efficiencies for the lab and streamlined testing to aid in diagnosis and faster initiation of treatment

icon-link.pngInstructions for Use

VIEW ORDERING INFORMATION

Product Details
 

INTENDED USE

The Alinity m HCV assay is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay for both the detection and quantitation of hepatitis C virus (HCV) RNA, in human plasma (EDTA, Acid Citrate Dextrose) or serum, from HCV antibody positive individuals. The assay is intended for use as an aid in the diagnosis of active HCV infection in individuals with antibody evidence of HCV infection, and to aid in the management of patients with known active HCV infection, including Sustained Virologic Response (SVR) determination.

The results from the Alinity m HCV assay must be interpreted within the context of all relevant clinical and laboratory findings.

The Alinity m HCV assay is not intended to be used in screening blood, plasma, serum, tissue or tissue donors for HCV.

LIMITATIONS OF THE PROCEDURE

  • Optimal performance of this test requires appropriate specimen collection and handling (refer to the SPECIMEN COLLECTION AND PREPARATION FOR ANALYSIS section of the package insert).
  • Human serum (including serum separator and rapid-clot tubes) and plasma (ACD, K2 EDTA, K3 EDTA, and PPT) specimens may be used with the Alinity m HCV assay. The use of other plasma and serum tubes has not been evaluated.
  • Debris within serum and plasma specimens (eg, clots, fibrin strands) may interfere with sample processing.
  • The instruments and assay procedures reduce the risk of contamination by amplification product. However, nucleic acid contamination from the calibrators, positive controls, or specimens must be controlled by good laboratory practice and careful adherence to the procedures specified in this package insert.
  • Though rare, mutations within the highly conserved regions of a viral genome covered by the Alinity m HCV may affect primer and/or probe binding resulting in the under‐quantitation of virus or failure to detect the presence of virus. The Alinity m HCV assay mitigates this risk by utilizing two unique probes in a highly conserved region of the HCV genome.
  • Assay performance characteristics have been established for individuals treated with certain direct-acting antiviral agents (DAA) regimens. No information is available on the assay’s predictive value when other DAA combination therapies are used.

For in vitro diagnostic use

Rx Only

 

specifications
 

 

ABBOTT ALINITY m HCV ASSAY PERFORMANCE1-5
Technology RT-PCR
Claim Viral load monitoring and confirmation of active HCV infection
Time to Result < 115 min
Standardization 4th WHO International Standard for Hepatitis C Virus RNA, NIBSC code: 06/102
Probe Design Dual probe design; robust genotyping detection
Target Region Conserved 5’ UTR Region  
Genotypes 1, 2, 3, 4, 5, 6  
Specimen Types

 

Plasma: Acid Citrate Dextrose (ACD); K2EDTA; K3EDTA, Plasma Preperation Tubes (PPT)

Serum: Serum; Serum separator tubes (SST), Serum Rapid-Clot Tube

Sensitivity / Limit of Detection (LoD)

12 IU/mL                                                                                                                                                                                                                             

Plasma: Probe Analysis determined that the concentration of HCV RNA detected with 95% probability was 8.50 IU/mL                               

Serum: Probe Analysis determined that the concentration of HCV RNA detected with 95% probability was 7.96 IU/mL
Result Units

IU/mL or log IU/mL
Precision

Plasma: SD ≤ 0.19 log IU/mL

Serum: SD≤ 0.23 log IU/mL
Controls

 

Negative, Low Positive, and High Positive controls 
Sample Input Volume 600 µL 
Calibrator 2 Calibrator Levels
Internal Control Armored RNA (Pumpkin)
1. Alinity m HCV AMP Kit Package Insert (PI): 53-608166/R1  2. Alinity m HCV CAL Kit PI: 53-608167/R4  3. Alinity m HCV Control Kit PI: 53-608168/R1  4. Alinity m Operators Manual 54-60513 R6  5. Abbott Data on File 
 
 

Ordering Info

Back

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No